Raltegravir and Etravirine Are Active against HIV Type 1 Group O

被引：32

作者：

Briz, Veronica ^{[1
]}

Garrido, Carolina ^{[1
]}

Poveda, Eva ^{[1
]}

Morello, Judit ^{[1
]}

Barreiro, Pablo ^{[1
]}

de Mendoza, Carmen ^{[1
]}

Soriano, Vincent ^{[1
]}

机构：

[1] Hosp Carlos III, Dept Infect Dis, Madrid 28040, Spain

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2009年 / 25卷 / 02期

关键词：

D O I：

10.1089/aid.2008.0222

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The activity of raltegravir and etravirine was assessed in vitro in HIV-1 group O isolates. Despite the presence of some natural polymorphisms associated with resistance to raltegravir (V72I, L74I, S153A, V201I, and T206S) and etravirine (G190A), both drugs showed significant antiviral activity. Subsequently, the clinical benefit was shown in an HIV-1 group O-infected individual in whom enfuvirtide was replaced by raltegravir. Therefore, individuals infected with HIV-1 group O might benefit from raltegravir and/or etravirine therapy.

引用

页码：225 / 227

页数：3

共 16 条

[1] TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1
Andries, K
Azijn, H
Thielemans, T
Ludovici, D
Kukla, M
Heeres, J
Janssen, P
De Corte, B
Vingerhoets, J
Pauwels, R
de Béthune, MP
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) : 4680 - 4686
[2] Garrido C, 2008, 6 EUR HIV DRUG RES W
[3] GARRIDO C, 2007, 47 INT C ANT AG CHEM
[4] HARRIS M, 2008, 15 C RETR OPP INF BO
[5] HAUBRICH R, 2008, 15 C RETR OPP INF BO
[6] Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel
Hirsch, Martin S.
Guenthard, Huldrych F.
Schapiro, Jonathan M.
Brun-Vezinet, Francoise
Clotet, Bonaventura
Hammer, Scott M.
Johnson, Victoria A.
Kuritzkes, Daniel R.
Mellors, John W.
Pillay, Deenan
Yeni, Patrick G.
Jacobsen, Donna M.
Richman, Douglas D.
[J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (02) : 266 - 285
[7] JOHNSON M, 2008, 15 C RETR OPP INF BO
[8] Lataillade M, 2007, ANTIVIR THER, V12, P563
[9] Marcelin AG, 2008, ANTIVIR THER, V13, pA68
[10] MARKOWITZ M, 2006, J ACQ IMMUN DEF SYND, V4, P509

← 1 2 →